UNSPSC 51372315: Carfentanil

This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, LA9DTA2L8F chemically known as 4-piperidinecarboxylic acid, 4-((1-oxopropyl)phenylamino)-1-(2-phenylethyl)-, methyl ester but generally known as carfentanil, which bears US NIH Compound Identifier 62156. European Medicines Agency schedules Carfentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06626MIG.

UNSPSC 51372315 Carfentanil is a Commodity code that does not align with the recent state and local solicitations posted under it. The code nominally covers carfentanil, a potent synthetic opioid used in limited medical and veterinary contexts, yet the three recent opportunities show no procurement of carfentanil itself. Instead, issuing bodies are buying naloxone and drug deactivation systems (opioid antagonists and harm-reduction equipment), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploring direct-to-manufacturer pharmacy prescription programs. The mismatch suggests that either the code has been misapplied to these opportunities or state and local procurement databases are tagging broader pharmaceutical and naloxone-related activity under this narrow commodity code. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). The lack of carfentanil-specific procurement warrants clarification of whether this code remains actively used for its nominal product or if the actual buying activity has migrated to different UNSPSC categories.

Recent opportunities span Florida, Texas, Minnesota, and Oregon, clustered around opioid response, pharmaceutical distribution, and pharmacy benefit administration rather than carfentanil procurement. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, a preliminary information-gathering phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) on January 20, 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products available through three authorized wholesalers, with proposals due March 26, 2026 and contract awards effective July 1, 2026. None of these solicitations target carfentanil; the code shows little relevant recent activity aligned with its nominal scope.